EP Patent

EP4101859A1 — 4'-oxymethylphosphonate nucleotide analogs and oligonucleotides comprising the same

Assigned to Novo Nordisk AS · Expires 2022-12-14 · 3y expired

What this patent protects

Disclosed herein are oligonucleotides, such as nucleic acid inhibitor molecules, having a 4'-oxymethylphosphonate group and methods of using the same, for example, to modulate the expression of a target gene in a cell. The phosphate analogs are bound to the 4'-carbon of the sugar…

USPTO Abstract

Disclosed herein are oligonucleotides, such as nucleic acid inhibitor molecules, having a 4'-oxymethylphosphonate group and methods of using the same, for example, to modulate the expression of a target gene in a cell. The phosphate analogs are bound to the 4'-carbon of the sugar moiety (e.g., a ribose or deoxyribose or analog thereof) of the 5'-terminal nucleotide of an oligonucleotide.

Drugs covered by this patent

Patent Metadata

Patent number
EP4101859A1
Jurisdiction
EP
Classification
—
Expires
2022-12-14
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.